v

Corporate Presentation

September 2017

Safe harbor statement

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of

the Securities Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections. Forward-looking

statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of

forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," “goal,” "estimate ," "anticipate" or other

comparable terms. All statements other than statements of historical facts included in this presentation regarding our strategies, prospects, financial

condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others,

statements we make regarding expected future operating results, anticipated results of our sales and marketing efforts, expectations concerning payor

reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of

future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans

and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the

future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our

control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not

rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from

those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and

services; the acceptance of our products and services by patients and healthcare providers; the willingness of health insurance companies and other

payors to cover Cologuard and reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer

screening products and services; the effects of any healthcare reforms, including the Affordable Care Act, or changes in healthcare pricing, coverage and

reimbursement; recommendations, guidelines and/or quality metrics issued by various organizations such as the U.S. Preventive Services Task Force,

the American Cancer Society and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to

successfully develop new products and services; our success establishing and maintaining collaborative licensing and supplier arrangements; our ability

to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in

Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K

and our subsequently filed Quarterly Report(s) on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether

written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

2

OUR MISSION

To partner with patients, healthcare

providers, payers & advocacy groups to

help eradicate colon cancer

3

Source: American Cancer Society, Cancer Facts & Figures 2017; all figures annual

Colon cancer: America’s second deadliest cancer

new diagnoses in 2015

15,690

26,730

41,070 43,09050,260

155,870

Esophageal Prostate Breast Pancreas Colorectal Lung

Annual cancer deaths

132,700

deaths in 2015

49,700

135,430new diagnoses

50,260deaths

4

10+ years

Sources: J Natl Cancer Inst. 2009; 101:1225-1227 (Itzkowitz)

Gastro 1997;112:594-692 (Winawer)

Pre-cancerous polyp Cancer

5

“The most preventable, yet

least prevented form of cancer”– Journal of the National Cancer Institute

Sources: SEER 18 2004-2010

American Cancer Society, Cancer Facts & Figures 2017; all figures annual

Detecting colorectal cancer early is critical

9 out of 10

survive 5 years

Diagnosed in Stages I or II Diagnosed in Stage IV

1 out of 10

survive 5 years

Majority of patients diagnosed in stages III-IV

6

Rx Only

50%52%

59% 58%62%

80% goal

2005 2008 2010 2013 2015 2018

Sources: CDC NHIS survey results as published in the CDC’s MMWR between 2006 and 2017

Actual colon cancer screening rates

America’s stagnant colon cancer screening rate

7

Rx OnlySource: Imperiale TF et al., N Engl J Med (2014)

developed with

Cologuard: Addressing the colon cancer challenge

94% early-stage cancer sensitivity

Easy-to-use & non-invasive while requiring

no preparation, sedation, or time off work

FDA approved & included in major guidelines

Insurance coverage for 86% of addressable

population (80M+ people), including Medicare

8

9Source: Mayo Clinic poster presentation Su1044, Digestive Disease Week 2016

Knowledge of positive Cologuard improves

colonoscopy performance

46% more time spent

on colonoscopy

Mayo Clinic study compares results of unblinded, blinded colonoscopies

2xPolyps

discovered

32%Increase in

pre-cancer detection

4xHigher flat right-sided

lesion detection

Welcome call 24/7 patient

support line

Cologuard

delivered to home

Reminder call

Reminder letter

66Patient compliance

Driving patient compliance with colon cancer screening

Cologuard’s compliance rate is derived from the number of completed tests reported divided by the number of collection kits

shipped to patients during the 12-month period ending 60 days prior to June 30, 2017, excluding program orders.

10

%

Sources: *Patient adherence over 3 years’ Liang PS., et al., Am J Gastroenterol. 2016

**Patient compliance within 1 year; Arch Intern Med 2012; 172(7):575-582 (Inadomi)

***Cologuard’s compliance rate is derived from the number of completed tests reported divided by the number of collection kits shipped to

patients during the 12-month period ending 60 days prior to June 30, 2017, excluding program orders.

11

Impact of patient navigation service on compliance

colonoscopy**

38%

***

66%

FOBT*

14%

11

Cologuard increases patient complianceUSMD study highlights opportunity to expand screening & detect curable-stage cancer

American Association of Cancer Research Annual meeting 2016, New Orleans LA USA, LB-296,

Proceedings of the American Association of Cancer Research, in press

Non-compliant

Medicare

patients

393Cancers in

curable stage;

21 advanced

adenoma

4Cologuard

compliance

88%

12

*Exact Sciences internal estimates based upon prevalence and detection rates from DeeP-C study

(Imperiale TF et al., N Engl J Med (2014)

Impact of Cologuard during second quarter 2017*

~600early-stage

cancers

~200late-stage

cancers

135,000completed

Cologuard tests

Early-stage colorectal cancer detected in more than 6 patients a day

13

Strong customer satisfaction with Cologuard

Physicians’

expectations

met or exceeded 96%

Patients rated

Cologuard experience

very positive89%Sources: ZS survey conducted for Exact Sciences Oct-Dec 2016, n=300

Exact Sciences Laboratories patient satisfaction survey Jan-Jun 2017; n = 2,91914

15

Commercial strategy engages key audiences

National TV

campaign

and digital

marketing

Patients

Payers

Market access team and

clinical & health publications

Primary care

sales force

and collateral

materialsPhysicians &

Systems

Patients

National TV campaign increasing ordering & adoption

16

Exact Sciences nationwide sales force:

Establishing a new standard for colon cancer screening

Primary care sales force

• Focus on top potential physician offices

• Educate physicians & office staff

• Improve repeat ordering of Cologuard

Inside sales force

• Extend reach of sales force coverage

• Support field in education efforts

• New physician outreach and pull through

17

$1.5 $4.3

$8.1 $12.6 $14.4 $14.8

$21.2

$28.1

$35.2

$48.4

$57.6

Cologuard revenue growth

2015 2016

Quarterly Cologuard revenue ($ Millions)18

Launch of

national

TV campaign

2017

$383 $386

$393

$405

$418 $423

Time-lagged average revenue per test improving

2016

19

2017

Note: average Cologuard reimbursement from all sources on a trailing

12 month basis for tests that were completed at least 6 months ago

2%***

20

A multi-billion dollar U.S. market opportunity

*80 million average-risk, asymptomatic people ages 50-85

**Assumes average revenue per test of $500-525 and 3-year testing interval for Cologuard

***(135,000 completed tests * 4 to annualize * 3 to account for testing interval) / 80M

80M+Potential U.S. screening

market for Cologuard*

$14B Total Addressable Market**

4,0008,000

15,00021,000

27,000

32,000

41,000

50,000

60,000

70,000

81,000Cologuard’s growing provider penetration

2015 2016

Cumulative Cologuard ordering providers

2017

Launch of

national

TV campaign

21

Coverage accelerated following Cologuard inclusion in

USPSTF recommendations

2015 2016

236M total

USPSTF

Source: US Census data, AIS Directory of Health Plans: 2016, Exact Sciences Analysis 22

86% of Cologuard’s addressable market covered

2017

Cologuard becoming the standard of care

Additional coverage driven by data, guidelines and quality measures

23

>85%

insurance

coverage

2009-2013 2014 2015 2017

developed

with Mayo

Clinic

10,000

patient

DeeP-C trial guidelines

HEDIS quality

measures

Medicare

Star Ratings

coverage

approval

&

2016

guidelinesreconfirmed

performance

recommended

by USPSTFtrial results

published

Cologuard: Increasing America’s screening population

Exact Sciences Laboratories patient survey data May-Jun 2017; n = 993

38% screened with

colonoscopy

51% never

screened before

11% screened only

with FIT/FOBT

Screening history of

Cologuard users

24

25

Exact Sciences is a data-driven companyInformation from over 585,000 patients and 81,000 physicians

Increase compliance and

repeat screeningPatients

Improve quality measures

and outcomesPhysicians

Improve quality measures

and reporting capabilitiesPayers

Building a pipeline on Cologuard platform

27

14Mnew cancer

cases &

8.8Mdeaths

Source: World Health Organization and Centers for Disease Control and Prevention

Cancer’s annual impact nationally and globally

1.6Mnew cancer

cases &

600kdeaths

Expected 70% increase in new cases within 20 years

Unique collaboration & platform target deadliest cancers

Regulatory, scientific,

and commercial

expertise

Exact SciencesClinical trials, access

to samples, and key

opinion leader support

Mayo ClinicQuARTS™ PCR

chemistry and Cologuard

instrumentation

Technology Platform

Identifying specific, proprietary cancer DNA markers to facilitate early detection

28

29

Advantages of the Exact Sciences approach

Methylation markers enable cancer site specificity

Cost advantages over Next-Generation Sequencing (NGS)

High specificity & sensitivity achieved with few markers

Source: Analyst estimates

Liquid biopsy: A growth area for cancer diagnostics

2015 2030

Projected

liquid biopsy

market

>$13B

$200M

Exact Sciences focusing on early detection & recurrence

Screening

Diagnostic aid

Minimum residual disease

Recurrence monitoring

Response monitoring

Response profiling

Targeted therapy selection

Clinical applications

30

31

A need and opportunity in diagnosing lung cancer

Biopsy

Surgery

1.5-3M lung

nodules discovered

annually*

$750M

to $1.5BInvasive,

expensive, and

harmful

The

Problem

Current

Options

Potential

Opportunity

Blood-based

biomarker test

**

*Gould et al., Am J Respir Crit Care Med (2015)

**Total Addressable Market assumes average revenue per test of $500

CT

scans

Second-quarter 2017 financial results

Second Quarter

2017

Revenue $57.6 million $48.4 million

Gross margin 69% 65%

Operating expense $71.1 million $66.9 million

Cash utilization $43.9 million $36.4 million

Ending cash balance $484.3 million $274.7 million

32

First Quarter

2017